Anesth Pain Med.  2023 Jan;18(1):11-20. 10.17085/apm.22259.

Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations

• Oh SK
• Lim BG

• KMID: 2540329
• DOI: http://doi.org/10.17085/apm.22259

Abstract

Due to unknown safety concerns, sugammadex should not be administered to patients withend-stage renal disease (ESRD). However, because the supply of benzylisoquinolinium-typeneuromuscular blocking agents (NMBAs) has been discontinued, rocuronium is the onlynon-depolarizing NMBA that can be used in clinical settings in some countries, includingSouth Korea. The administration of sugammadex cannot be avoided to achieve rapid andcomplete neuromuscular recovery in patients with ESRD or renal transplantation after rocuronium administration. Although there has been a limited number of clinical studies involving the use of sugammadex in patients with ESRD, studies have shown that sugammadexcan effectively and safely reverse rocuronium-induced neuromuscular blockade (NMB) inpatients with ESRD, however recovery of neuromuscular function in patients with ESRD isslower than in patients with normal renal function. Nonetheless, safety-concerns are yet tobe addressed. Considering the small number of clinical studies, high heterogeneity amongstudies, and insufficient safety information, more extensive data on the efficacy and safetyof sugammadex in patients with ESRD are needed. In particular, it is important to securedata on safety, including residual NMB after surgery, recurarization and cardiorespiratorycomplications, anaphylactic reactions, and long-term morbidity and mortality. Furthermore,anesthesiologists should remember that performing proper quantitative neuromuscularmonitoring and neuromuscular management based on the monitoring signs are the mostessential requirements when using sugammadex in patients with ESRD.

Keyword

Drug-related side effects and adverse reactions; Chronic kidney failure; End-stage renal disease; Neuromuscular blockade; Rocuronium; Sugammadex

Reference

1. Lee HY, Jung KT. Advantages and pitfalls of clinical application of sugammadex. Anesth Pain Med (Seoul) 2020; 15: 259-68. Erratum in: Anesth Pain Med (Seoul). 2022; 17:341.

2. Cho SA, Sung TY. Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications. Anesth Pain Med (Seoul). 2022; 17:121–31.

3. Merck Sharp & Dohme Corp. BRIDION® (sugammadex) injection, for intravenous use Initial U.S. approval: 2015. U.S. Food and Drug Administration [Internet]. 2015 Dec [cited 2019 Dec 5]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf.

4. Kim YS, Lim BG, Won YJ, Oh SK, Oh JS, Cho SA. Efficacy and safety of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in patients with end-stage renal disease: a systematic review and meta-analysis. Medicina (Kaunas). 2021; 57:1259.

5. Song S, Cho HB, Park SY, Koo WM, Choi SJ, Yoon S, et al. Postoperative mortality in patients with end-stage renal disease according to the use of sugammadex: a single-center retrospective propensity score matched study. Anesth Pain Med (Seoul). 2022; 17:371–80.

6. Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008; 101:492–7.

7. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010; 104:31–9.

8. de Souza CM, Tardelli MA, Tedesco H, Garcia NN, Caparros MP, Alvarez-Gomez JA, et al. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: a comparative prospective clinical trial. Eur J Anaesthesiol. 2015; 32:681–6.

9. Panhuizen IF, Gold SJ, Buerkle C, Snoeck MM, Harper NJ, Kaspers MJ, et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Br J Anaesth. 2015; 114:777–84.

10. Min KC, Lasseter KC, Marbury TC, Wrishko RE, Hanley WD, Wolford DG, et al. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
. Int J Clin Pharmacol Ther. 2017; 55:746–52.

11. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007; 106:935–43.

12. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006; 104:667–74.

13. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007; 104:575–81.

14. Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth. 2012; 109:382–90.

15. Adams DR, Tollinche LE, Yeoh CB, Artman J, Mehta M, Phillips D, et al. Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. Anaesthesia. 2020; 75:348–52.

16. Paredes S, Porter SB, Porter IE 2nd, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. Can J Anaesth. 2020; 67:1789–97.

17. Valente A. High need for sugammadex for rocuronium reversal with acute renal failure and normal need in the same patient with no renal impairment. J Clin Anesth. 2020; 67:109981.

18. Unterbuchner C. Use of rocuronium and sugammadex in renal transplantation: problems that must be considered. Eur J Anaesthesiol. 2016; 33:690–1.

19. Ono Y, Fujita Y, Kajiura T, Okawa H, Nakashima J, Isobe H, et al. Efficacy and safety of sugammadex in patients undergoing renal transplantation. JA Clin Rep. 2018; 4:56.

20. Arslantas R, Cevik BE. Retrospective investigation of grafted kidney function after reversal of neuromuscular blockade using neostigmine or sugammadex. Transplant Proc. 2019; 51:2265–7.

21. Vargas M, Buonanno P, Sica A, Sabatella E, D'Alessio FP, Alfieri S, et al. Effects of sugammadex plus rocuronium vs neostigmine plus cisatracurium during renal transplantation on graft function: a retrospective, case-control study. Transplant Proc. 2021; 53:818–24.

22. Carron M, Andreatta G, Pesenti E, De Cassai A, Feltracco P, Linassi F, et al. Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study. Perioper Med (Lond). 2022; 11:3.

23. Magoon R, Kashav R, Kohli JK. Sugammadex in end-stage renal disease: too early for a "free-pass". Can J Anaesth. 2021; 68:264–5.

24. Kapoor MC. Cardiovascular adverse effects of sugammadex. J Anaesthesiol Clin Pharmacol. 2020; 36:469–70.

25. Tercan M, Yılmaz İnal F, Seneldir H, Kocoglu H. Nephroprotective efficacy of sugammadex in ischemia-reperfusion injury: an experimental study in a rat model. Cureus. 2021; 13:e15726.